Scarica l'app Stockscreener
12.51
9.22%
-1.27
Precedente Chiudi:
$13.78
Aprire:
$14.4
Volume 24 ore:
180.71K
Relative Volume:
8.88
Capitalizzazione di mercato:
$98.24M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.08%
1M Prestazione:
+14.25%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$12.00
$23.76
Intervallo di 1 settimana:
$12.00
$23.76
Portata 52W:
$10.00
$23.76
Jatt Ii Acquisition Corp Stock (JATT) Company Profile
Nome
Jatt Ii Acquisition Corp
Settore
Industria
Telefono
201-688-0364
Indirizzo
C/O APPLEBY GLOBAL SERVICES (CAYMAN) LTD, GEORGE TOWN
Compare JATT vs XXI, LION, UMAC, CCXI, DMII
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JATT
Jatt Ii Acquisition Corp
|
12.59 | 105.50M | 0 | 0 | 0 | 0.00 |
XXI
Twenty One Capital Inc
|
6.445 | 3.12B | 0 | 4.35M | 456.40K | 0.3397 |
LION
Lionsgate Studios Corp
|
11.46 | 3.45B | 2.63B | -175.60M | 11.40M | -0.7173 |
UMAC
Unusual Machines Inc
|
27.39 | 1.41B | 17.25M | -5.64M | -40.16M | -0.3337 |
CCXI
Churchill Capital Corp Xi
|
14.61 | 813.22M | 0 | 0 | 0 | 0.0647 |
DMII
Drugs Made In America Acquisition Ii Corp
|
10.14 | 644.64M | 0 | 8.58M | -1.11M | 0.134 |
Jatt Ii Acquisition Corp Borsa (JATT) Ultime notizie
Balyasny Asset Management L.P. Initiates Position in JATT II Acq - GuruFocus
ADAR1 Capital Management (JATT) discloses 5.4% beneficial stake in JATT II - Stock Titan
JATT II Acquisition Corp. (JATT) investors file update showing 0% stake - Stock Titan
JATT II Acquisition Corp (JATT) reports 6.23% stake held by Great Point - Stock Titan
Atika Capital (JATT) discloses 5.1% beneficial stake in JATT II Acquisition Corp. - Stock Titan
Balyasny Asset Management (JATT) discloses 6.23% holding in JATT II common stock - Stock Titan
Janus Henderson Group (JATT) discloses 6.2% beneficial stake in JATT II - Stock Titan
JATT II Acquisition Corp. (JATT) plans Talawar merger backed by $225M PIPE - Stock Titan
JATT II Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
VSCTF Stock Price and Chart — OTC:VSCTF - TradingView
COPL|Copley Acquisition Corp|Price:10.480|Chg%:+0.010 - TradingKey
JATT II Acquisition Corp Revenue Breakdown – NASDAQ:JATT - TradingView
FACT|FACT II Acquisition Corp|Price:10.660|Chg%:+0.010 - TradingKey
BBCQ|Bleichroeder Acquisition II Units|Price:10.170| - TradingKey
MACI|Melar Acquisition Corp I|Price:10.910|Chg%:+0.010 - TradingKey
ASPC|A SPAC III Acquisition Corp|Price:10.542|Chg%:-0.098 - TradingKey
SPEG|Silver Pegasus Acquisition Corp|Price:10.300| - TradingKey
WTG|Wintergreen Acquisition Corp|Price:10.490|Chg%:+0.020 - TradingKey
FSHP|Flag Ship Acquisition Corp|Price:11.110| - TradingKey
JATT|JATT II Acquisition Ord Shs|Price:13.290|Chg%:+1.080 - TradingKey
ENHA|A Paradise Acquisition Ord Shs Class A|Price:2.650|Chg%:+0.020 - TradingKey
Talawar Therapeutics Appoints Steve Migausky as Chief Legal and Administrative Officer - PR Newswire
Jatt Ventures Ii L.p. Net Worth (2026) - GuruFocus
Biotech-Focused Hedge Funds Back Talawar’s Fast Moving SPAC Merger - Institutional Investor
JATTJatt II Acquisition Corp Revenue Breakdown - Finviz
JATT II Acquisition (JATT) sponsor forfeits 225,000 shares after over-allotment expiry - Stock Titan
JATT II Acquisition Corp. (JATT) sponsor forfeits 225,000 Ordinary Shares - Stock Titan
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - AOL.com
Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger - Yahoo Finance
Price to book forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Talawar (NASDAQ: TLWR) to Merge with JATT II; $285M Expected - Stock Titan
Price to sales forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Price to earnings forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Talawar Therapeutics and JATT II Announce $285M Merger to Advance Bispecific Antibody for Atopic Dermatitis - Minichart
Talawar–JATT II deal includes $225M PIPE (NASDAQ: JATT) - Stock Titan
Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone disease - Endpoints News
Talawar Tx launches as publicly traded biotech - The Pharma Letter
Enterprise value to revenue forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
Enterprise value to EBIT forward of JATT II Acquisition Corp – NASDAQ:JATT - TradingView
JATT II Acquisition to Merge With Talawar Tx; JATT to Become Subsidiary in SPAC Deal - TradingView
Talawar, JATT II (Nasdaq: JATT) unveil $225M PIPE-backed biotech merger - Stock Titan
Talawar Therapeutics To Go Public Through A SPAC Deal With JATT II Acquisition - Pulse 2.0
JATT II Acquisition, Talawar Therapeutics announce combination agreement - TipRanks
Press Release: Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - Moomoo
Talawar Tx Inc. entered into a definitive business combination agreement to acquire JATT II Acquisition Corp. from JATT Ventures II L.P. in a reverse merger transaction. - marketscreener.com
JATT II ACQUISITION CORP (JATT) Stock Chart - ChartMill
OCAC.U Stock Fund Price and Chart — BOATS:OCAC.U - TradingView
JATT Price Today: JATT II Acquisition Corp. Stock Price, Quote & Chart | MEXC - MEXC Exchange
BermudaAppleby Advises Amanat Acquisition In Its USD75M Initial Public Offering - Mondaq
JATT II Acquisition Corp 2026 Q1 SEC Filing: Financials, Management Discussion, and Regulatory Disclosures - Minichart
JATT II Acquisition Corp. 1Q 2026: Net income $(68,793), EPS $(0.05) — 10-Q Summary - TradingView
Jatt Ii Acquisition Corp Azioni (JATT) Dati Finanziari
Non sono disponibili dati finanziari per Jatt Ii Acquisition Corp (JATT). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):